- Home
- INSG vs IPHA Comparison
INSG vs IPHA Comparison
Compare INSG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSG
- IPHA
- Stock Information
- Founded
- INSG 1996
- IPHA 1999
- Country
- INSG United States
- IPHA France
- Employees
- INSG N/A
- IPHA N/A
- Industry
- INSG Telecommunications Equipment
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- INSG Telecommunications
- IPHA Health Care
- Exchange
- INSG Nasdaq
- IPHA Nasdaq
- Market Cap
- INSG 170.2M
- IPHA 150.9M
- IPO Year
- INSG 2000
- IPHA 2019
- Fundamental
- Price
- INSG $12.67
- IPHA $1.95
- Analyst Decision
- INSG Buy
- IPHA Strong Buy
- Analyst Count
- INSG 3
- IPHA 1
- Target Price
- INSG $14.33
- IPHA $11.50
- AVG Volume (30 Days)
- INSG 103.3K
- IPHA 50.9K
- Earning Date
- INSG 02-19-2025
- IPHA 03-20-2025
- Dividend Yield
- INSG N/A
- IPHA N/A
- EPS Growth
- INSG N/A
- IPHA N/A
- EPS
- INSG N/A
- IPHA N/A
- Revenue
- INSG $207,478,000.00
- IPHA $36,202,722.00
- Revenue This Year
- INSG $3.60
- IPHA N/A
- Revenue Next Year
- INSG N/A
- IPHA $101.65
- P/E Ratio
- INSG N/A
- IPHA N/A
- Revenue Growth
- INSG 12.59
- IPHA N/A
- 52 Week Low
- INSG $2.08
- IPHA $1.29
- 52 Week High
- INSG $20.67
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- INSG 59.30
- IPHA 56.50
- Support Level
- INSG $11.23
- IPHA $1.72
- Resistance Level
- INSG $12.39
- IPHA $1.92
- Average True Range (ATR)
- INSG 0.64
- IPHA 0.10
- MACD
- INSG 0.13
- IPHA 0.02
- Stochastic Oscillator
- INSG 92.93
- IPHA 100.00
About INSG Inseego Corp.
Inseego Corp is into the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by applications software and cloud services designed to enable customers to easily analyze data insights and configure and manage their hardware. It generates maximum revenue from United States and Canada. The company also has a presence in Australia and Europe (including United Kingdom).
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.